Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus TESULOID.
DELATESTRYL vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category C
Category C
Androgen
Androgen